Clinipace Acquires Worldwide Clinical Research, Inc.

Company Expands to Enhance its Global Clinical Operations Capabilities and
Therapeutic Practice Areas

MORRISVILLE, N.C.--(Business Wire)--
Clinipace, a global technology-driven clinical research organization (CRO),
announced today that on October 26th, 2009 the company closed its acquisition of
Worldwide Clinical Research, Inc. (WWCR), a Midwest-based CRO specializing in
the management of clinical studies for biotechnology and pharmaceutical
companies. With the acquisition, Clinipace has changed its name to Clinipace
Worldwide.

Combined, the companies have managed over 70 contract research projects
conducted globally at almost 3,000 sites with 100,000 patients. With specific
expertise in oncology, among other therapeutic areas, the company will offer
fully-integrated technology-based clinical research solutions and services to
growth-oriented and mid-tier biopharmaceutical and medical device firms.

WWCR currently provides core clinical operations functionality including
monitoring, site management, and project management. These services will now be
augmented by Clinipace`s focus on technology-driven clinical research solutions
to provide clients with full-service, global research services that result in
greater trial visibility, more project control, and lower costs.

With the addition of more than 30 employees, the company headquarters will
remain in Research Triangle Park, NC with additional domestic operations in
Overland Park, KS, and South American operations based in Sao Paulo, Brazil,
Buenos Aires, Argentina, and Lima, Peru. Clinipace has experienced triple digit
growth over the past 12 months and is expected to continue to hire in all
locations throughout 2010 to support its growing CRO business.

"Having honed our expertise on electronic data management services, we felt it
was critical to expand both our clinical operations expertise and global
presence in order to support our growth," said Jeff Williams, Clinipace CEO. "As
one of the industry`s most trusted CROs, WWCR`s reliable service, global access
to enrolling sites, and program-level therapeutic experience will be a natural
complement to our existing research model and global expansion strategy.

Barbara Geiger, president and CEO of WWCR, will transition to Executive Vice
President of Clinical Operations and will be responsible for directing all
clinical operations for Clinipace Worldwide, Inc. from the Overland Park, KS
office. Geiger brings over 25 years of experience in the conduct and management
of Phase I-IV clinical trials and in the evaluation and selection of global
clinical trial vendors. Prior to founding WWCR in 2000, she spent ten years at
global CROs where she was Director of Project Management and Director of
International Partners.

"By combining forces, we can better serve our clients with a fully-integrated
end-to-end development solution and expert services," said Barb Geiger,
Executive Vice President of Clinical Operations. "The synergies between WWCR and
Clinipace will provide our clients with a complete range of technology-driven
services, ranging from clinical operations all the way through regulatory
submission."

"Vaccinogen selected Clinipace Worldwide for its upcoming global clinical trial
due, in part, to the combined strength of both companies and experience managing
phase 3 international oncology trials," said Michael G. Hanna, Jr., Ph.D.,
Founder, Chairman & CEO of Vaccinogen. "We are confident their therapeutic and
operations experts, along with their technology platform, will enable us to
centrally manage a very complex protocol with some very unique requirements."

About Clinipace Worldwide

Clinipace Worldwide is a global technology-driven clinical research organization
(CRO) specializing in fully-integrated clinical research services for
growth-oriented and mid-tier biopharmaceutical and medical device firms. Its
team of therapeutic experts brings extensive investigator site selection,
patient recruitment, clinical operations, data management, EDC software,
biostatistics, and regulatory knowledge and insight into successful clinical
development through proactive clinical trial management. With specific expertise
in oncology, among other therapeutic areas, Clinipace Worldwide has managed over
70 contract research projects conducted at almost 3,000 sites with 100,000
patients. Clinipace Worldwide is headquartered in Research Triangle Park, NC
with additional domestic operations in Overland Park, KS, and South American
operations based in Brazil, Argentina, and Peru. For more information visit our
website at clinipace.com.

Crossroads Public Relations for Clinipace
Molly Thompson, 919-821-2822
mthompson@crossroadspr.com

Copyright Business Wire 2009